OraSure Technologies, Inc.

OraSure Technologies, Inc.

OSURNYSE / NASDAQHealthcareSmall cap

$3.46-$0.15 (-4.2%)

Last close · Data as of Nov 20, 2026

Market cap
$287.1M
P/E
-4.2x
EV / EBITDA
-1.7x
Revenue
$115.0M
Net margin
-59.8%
ROCE
-18.7%

+64.0% over the last year

OraSure Technologies, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-7.7%
3M
-7.5%
6M
+12.7%
1Y
+64.0%
5Y
-64.8%

52-week range

Day change -$0.15 (-4.2%) from $3.61 to $3.46 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in OSUR, bought on each weekday since 2021.

News & filings

What OraSure Technologies filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 68.7 million US dollars in fiscal 2025.

Strengths (1)

  • Cash on the balance sheet equals 69% of the company's market value.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally.

Read moreShow less

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

Sector
Healthcare
Shares outstanding
70.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$287.1M
P/E
-4.2x
P/B
0.8x
EV / EBITDA
-1.7x
EV / Sales
0.9x
P/S
2.5x
52-week high
$4.50
52-week low
$2.11

Profitability

Operating margin
-59.2%
Net margin
-59.8%
EBITDA margin
-50.6%
ROE
-20.2%
ROCE
-18.7%
ROIC
-34.8%
ROA
-17.0%
Asset turnover
0.29

Growth

Revenue
$115.0M
Revenue growth, 1Y
-38.1%
Revenue CAGR, 3Y
-33.3%
Net profit growth, 1Y
252.5%
Free cash flow
-$53.2M

Solvency

Current ratio
6.58
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
0.71
Cash / Market cap
69.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$115.0M
Cost of revenue$66.8M
Gross profit$48.2M
Operating expenses$116.3M
Research and development$42.5M
Selling, general and administrative$73.8M
Operating income-$68.1M
Interest and other$3.5M
Pretax income-$64.6M
Tax and other$4.1M
Net income-$68.7M

Revenue and net profit

Revenue fell 38.1% in FY2025; net profit is the dashed line.

OraSure Technologies, Inc. revenue and net profit by fiscal year
OraSure Technologies, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$387.5M-$17.1M
FY2023$405.5M$53.7M
FY2024$185.8M-$19.5M
FY2025$115.0M-$68.7M

Cash flows

FY2025: -$49.0M from operations, -$53.2M free after investment (dashed).

OraSure Technologies, Inc. operating and free cash flow by fiscal year
OraSure Technologies, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$47.2M-$111.1M
FY2023$141.6M$131.3M
FY2024$27.4M$23.6M
FY2025-$49.0M-$53.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$115.0M-38.1%1Y
EBITDA
-$58.2M
Net profit
-$68.7M
Cash from operations
-$49.0M-279.1%1Y
Free cash flow
-$53.2M-325.7%1Y
Revenue CAGR, 3Y
-33.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$115.0M-$58.2M-$68.7M-$53.2M-20.2%-38.1%+252.5%

Monthly returns

Month-by-month returns of OSUR across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$403.2M
Liabilities$62.3M
Equity$340.8M
Paid-in capital$531.4M
Retained earnings-$172.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; OSUR highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. OraSure Technologies, Inc. (this company)0.9x

Not shown (no positive earnings and no EV / Sales): Eledon Pharmaceuticals, Inc., Anavex Life Sciences Corp.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
OraSure Technologies, Inc.OSURthis company$287.1M-4.2x0.8x-20.2%-1.7x
Electromed, Inc.ELMD$304.0M40.3x7.0x17.4%26.7x
Carlsmed, Inc.CARL$302.8M-10.2x3.1x-30.0%-8.4x
Alpha Teknova, Inc.TKNO$291.1M-16.9x4.2x-25.1%-30.9x
Niagen Bioscience, Inc.NAGE$278.8M16.0x3.6x22.7%13.8x
Quantum-Si incorporatedQSI$278.7M-2.8x1.3x-46.0%-2.8x
Eledon Pharmaceuticals, Inc.ELDN$277.9M-6.1x3.4x-56.3%-3.1x
Entrada Therapeutics, Inc.TRDA$271.7M-1.9x0.9x-47.0%-1.5x
Anavex Life Sciences Corp.AVXL$261.3M-5.6x2.8x-48.9%—
Peer median—-4.2x3.2x-38.0%-2.8x

Year-to-date ROI

OSUR since 1 January, against earlier years.

Historical volatility

OSUR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

OraSure Technologies, Inc. operating margin by fiscal year
OraSure Technologies, Inc. operating margin by fiscal year
DateOperating margin
FY2022-1.4%
FY202310.7%
FY2024-12.8%
FY2025-59.2%
LineFY2025
Cost of revenueCost Of Revenue$66.8M
Gross profitGross Profit$48.2M
Operating expensesOperating Expense$116.3M
Research and developmentResearch And Development$42.5M
Total expensesTotal Expenses$183.1M
Pretax incomePretax Income-$64.6M

Learn while you research

Academy chapters picked for OraSure Technologies, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →